

100TH GENERAL ASSEMBLY State of Illinois 2017 and 2018 SB2889

Introduced 2/14/2018, by Sen. Chapin Rose

SYNOPSIS AS INTRODUCED:

New Act 105 ILCS 5/22-30

Creates the Epinephrine Administration Act. Provides that a health care practitioner may prescribe epinephrine pre-filled syringes in the name of an authorized entity where allergens capable of causing anaphylaxis may be present. Provides that an authorized entity may acquire and stock a supply of undesignated epinephrine pre-filled syringes provided the undesignated epinephrine pre-filled syringes are stored in a specified location. Requires each employee, agent, or other individual of the authorized entity to complete a specified training program before using a pre-filled syringe to administer epinephrine. Provides that a trained employee, agent, or other individual of the authorized entity may either provide or administer an epinephrine pre-filled syringe to a person whom the employee, agent, or other individual believes in good faith is experiencing anaphylaxis. Provides that training under the Act shall be valid for 2 years. Requires the Department of Public Health to approve training programs, to list the approved programs on the Department's website, and to include links to training providers' websites on the Department's website. Contains provisions concerning costs, limitations, and rulemaking. Defines terms. Amends the School Code. In provisions concerning epinephrine administration, provides that epinephrine may be administered with a pre-filled syringe. Makes conforming changes.

LRB100 19109 MJP 34369 b

FISCAL NOTE ACT MAY APPLY

1 AN ACT concerning health.

Be it enacted by the People of the State of Illinois, represented in the General Assembly:

- Section 1. Short title. This Act may be cited as the Epinephrine Administration Act.
- 6 Section 5. Definitions. As used in this Act:
- "Authorized entity" means any entity or organization, other than a school covered under Section 22-30 of the School 8 Code, in connection with or at which allergens capable of causing anaphylaxis may be present, including, but not limited 10 to, independent contractors who provide student transportation 11 to schools, recreation camps, colleges and universities, day 12 13 care facilities, youth sports leagues, amusement parks, 14 restaurants, sports arenas, and places of employment. The Department shall, by rule, determine what constitutes a day 15 16 care facility under this definition.
- "Department" means the Department of Public Health.
- "Epinephrine pre-filled syringe" means a pre-filled syringe of epinephrine used for the administration of a pre-measured dose of epinephrine into the human body that is equivalent to the dosages used in an auto-injector.
- "Health care practitioner" means a physician licensed to practice medicine in all its branches under the Medical

- 1 Practice Act of 1987, a physician assistant under the Physician
- 2 Assistant Practice Act of 1987 with prescriptive authority, or
- 3 an advanced practice nurse with prescribing authority under
- 4 Article 65 of the Nurse Practice Act.
- 5 "Pharmacist" has the meaning given to that term under
- 6 subsection (k-5) of Section 3 of the Pharmacy Practice Act.
- 7 "Undesignated epinephrine pre-filled syringe" means an
- 8 epinephrine pre-filled syringe prescribed in the name of an
- 9 authorized entity.
- 10 Section 10. Prescription to authorized entity; use;
- 11 training.
- 12 (a) A health care practitioner may prescribe epinephrine
- 13 pre-filled syringes in the name of an authorized entity for use
- in accordance with this Act, and pharmacists may dispense
- 15 epinephrine pre-filled syringes in accordance with a
- 16 prescription issued in the name of an authorized entity. Such
- 17 prescriptions shall be valid for a period of 2 years.
- 18 (b) An authorized entity may acquire and stock a supply of
- 19 undesignated epinephrine pre-filled syringes in accordance
- 20 with a prescription issued under subsection (a) of this
- 21 Section. Such undesignated epinephrine pre-filled syringes
- 22 shall be stored in a location readily accessible in an
- emergency and in accordance with the instructions for use of
- 24 the epinephrine pre-filled syringes. The Department may
- 25 establish any additional requirements an authorized entity

- 1 must follow under this Act.
 - (c) An employee or agent of an authorized entity or other individual who has completed training under subsection (d) of this Section may:
 - (1) provide an epinephrine pre-filled syringe to any individual on the property of the authorized entity whom the employee, agent, or other individual believes in good faith is experiencing anaphylaxis, or to the parent, guardian, or caregiver of such individual, for immediate administration, regardless of whether the individual has a prescription for an epinephrine pre-filled syringe or has previously been diagnosed with an allergy; or
 - (2) administer epinephrine from a pre-filled syringe to any individual on the property of the authorized entity whom the employee, agent, or other individual believes in good faith is experiencing anaphylaxis, regardless of whether the individual has a prescription for an epinephrine pre-filled syringe or has previously been diagnosed with an allergy.

The employee or agent of an authorized entity or other individual under this subsection must be at least 18 years old to provide an epinephrine pre-filled syringe or administer epinephrine from a pre-filled syringe under this subsection.

(d) An employee, agent, or other individual authorized must complete an anaphylaxis training program before he or she is able to provide or administer epinephrine from a pre-filled

7

8

9

10

11

12

13

14

15

16

17

18

21

22

23

24

25

26

1	syringe under this Section. Such training shall be valid for a
2	period of 2 years and shall be conducted by a nationally
3	recognized organization experienced in training laypersons in
4	emergency health treatment. The Department shall include links
5	to training providers' websites on its website.

Training shall include, but is not limited to:

- (1) how to recognize signs and symptoms of an allergic reaction, including anaphylaxis;
- (2) how to administer epinephrine from a pre-filled syringe; and
- (3) a test demonstrating competency of the knowledge required to recognize anaphylaxis and administer epinephrine from a pre-filled syringe.

Training may also include, but is not limited to:

- (A) a review of high-risk areas on the authorized entity's property and its related facilities;
 - (B) steps to take to prevent exposure to allergens;
 - (C) emergency follow-up procedures; and
- 19 (D) other criteria as determined in rules adopted 20 pursuant to this Act.
 - Training may be conducted either online or in person. The Department shall approve training programs and list permitted training programs on the Department's Internet website.
 - (e) A health care practitioner providing a prescription for epinephrine in accordance with this Act shall incur no liability or professional discipline, except for willful and

- 1 wanton misconduct, as a result of any injury arising from the
- 2 use of epinephrine under this Act.
- 3 Section 15. Costs. Whichever entity initiates the process
- 4 of obtaining undesignated epinephrine pre-filled syringes and
- 5 providing training to personnel for carrying and administering
- 6 epinephrine from undesignated epinephrine pre-filled syringes
- 7 shall pay for the costs of the undesignated epinephrine
- 8 pre-filled syringes.
- 9 Section 20. Limitations. The use of an undesignated
- 10 epinephrine pre-filled syringe in accordance with the
- 11 requirements of this Act does not constitute the practice of
- 12 medicine or any other profession that requires medical
- 13 licensure.
- Nothing in this Act shall limit the amount of epinephrine
- pre-filled syringes that an authorized entity or individual may
- 16 carry or maintain a supply of.
- 17 Section 85. Rulemaking. The Department shall adopt any
- rules necessary to implement and administer this Act.
- 19 Section 90. The School Code is amended by changing Section
- 20 22-30 as follows:
- 21 (105 ILCS 5/22-30)

Sec. 22-30. Self-administration and self-carry of astl	nma
medication and epinephrine <u>injectors</u> auto-injectors	rs ;
administration of undesignated epinephrine <u>injector</u>	ors
auto-injectors; administration of an opioid antagonist; astl	hma
episode emergency response protocol.	

(a) For the purpose of this Section only, the following terms shall have the meanings set forth below:

"Asthma action plan" means a written plan developed with a pupil's medical provider to help control the pupil's asthma. The goal of an asthma action plan is to reduce or prevent flare-ups and emergency department visits through day-to-day management and to serve as a student-specific document to be referenced in the event of an asthma episode.

"Asthma episode emergency response protocol" means a procedure to provide assistance to a pupil experiencing symptoms of wheezing, coughing, shortness of breath, chest tightness, or breathing difficulty.

"Asthma inhaler" means a quick reliever asthma inhaler.

"Epinephrine auto injector" means a single use device used for the automatic injection of a pre-measured dose of epinephrine into the human body.

"Epinephrine injector" includes an auto-injector for the administration of epinephrine or a pre-filled syringe used for the administration of epinephrine that contain a pre-measured dose of epinephrine that is equivalent to the dosages used in an auto-injector.

"Asthma medication" means a medicine, prescribed by (i) a

physician licensed to practice medicine in all its branches,

(ii) a licensed physician assistant with prescriptive

authority, or (iii) a licensed advanced practice registered

nurse with prescriptive authority for a pupil that pertains to

the pupil's asthma and that has an individual prescription

label.

"Opioid antagonist" means a drug that binds to opioid receptors and blocks or inhibits the effect of opioids acting on those receptors, including, but not limited to, naloxone hydrochloride or any other similarly acting drug approved by the U.S. Food and Drug Administration.

"School nurse" means a registered nurse working in a school with or without licensure endorsed in school nursing.

"Self-administration" means a pupil's discretionary use of his or her prescribed asthma medication or epinephrine <u>injector</u> auto <u>injector</u>.

"Self-carry" means a pupil's ability to carry his or her prescribed asthma medication or epinephrine <u>injector</u> auto-injector.

"Standing protocol" may be issued by (i) a physician licensed to practice medicine in all its branches, (ii) a licensed physician assistant with prescriptive authority, or (iii) a licensed advanced practice registered nurse with prescriptive authority.

"Trained personnel" means any school employee or volunteer

personnel authorized in Sections 10-22.34, 10-22.34a, and 10-22.34b of this Code who has completed training under subsection (g) of this Section to recognize and respond to anaphylaxis.

"Undesignated epinephrine <u>injector</u> auto <u>injector</u>" means an epinephrine <u>injector</u> auto <u>injector</u> prescribed in the name of a school district, public school, or nonpublic school.

- (b) A school, whether public or nonpublic, must permit the self-administration and self-carry of asthma medication by a pupil with asthma or the self-administration and self-carry of an epinephrine <u>injector</u> auto-injector by a pupil, provided that:
 - (1) the parents or guardians of the pupil provide to the school (i) written authorization from the parents or guardians for (A) the self-administration and self-carry of asthma medication or (B) the self-carry of asthma medication or (ii) for (A) the self-administration and self-carry of an epinephrine injector auto injector or (B) the self-carry of an epinephrine injector auto injector, written authorization from the pupil's physician, physician assistant, or advanced practice registered nurse; and
 - (2) the parents or guardians of the pupil provide to the school (i) the prescription label, which must contain the name of the asthma medication, the prescribed dosage, and the time at which or circumstances under which the

asthma me	edication is	to be	administ	ered,	or (ii	i) for	the
self-admi	nistration	or se	elf-carry	of	an e	pineph	rine
injector	auto-inject	or , a	written	stat	ement	from	the
pupil's	physician,	physic	cian ass	istant	c, or	adva	nced
practice	registered	nurs	e conta	ining	the	follo	wing
informati	on:						

- (A) the name and purpose of the epinephrine injector auto injector;
 - (B) the prescribed dosage; and
 - (C) the time or times at which or the special circumstances under which the epinephrine <u>injector</u> auto-injector is to be administered.
- The information provided shall be kept on file in the office of the school nurse or, in the absence of a school nurse, the school's administrator.
- (b-5) A school district, public school, or nonpublic school may authorize the provision of a student-specific or undesignated epinephrine <u>injector</u> auto <u>injector</u> to a student or any personnel authorized under a student's Individual Health Care Action Plan, Illinois Food Allergy Emergency Action Plan and Treatment Authorization Form, or plan pursuant to Section 504 of the federal Rehabilitation Act of 1973 to administer an epinephrine <u>injector</u> auto-injector to the student, that meets the student's prescription on file.
- (b-10) The school district, public school, or nonpublic school may authorize a school nurse or trained personnel to do

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

following: (i) provide an undesignated epinephrine the injector auto-injector to a student for self-administration only or any personnel authorized under a student's Individual Health Care Action Plan, Illinois Food Allergy Emergency Action Plan and Treatment Authorization Form, or plan pursuant to Section 504 of the federal Rehabilitation Act of 1973 to administer to the student, that meets the student's prescription on file; (ii) administer an undesignated epinephrine <u>injector</u> auto <u>injector</u> that meets the prescription on file to any student who has an Individual Health Care Action Plan, Illinois Food Allergy Emergency Action Plan and Treatment Authorization Form, or plan pursuant to Section 504 of the federal Rehabilitation Act of 1973 that authorizes the use of an epinephrine injector auto-injector; (iii) administer an undesignated epinephrine injector auto-injector to any person that the school nurse or trained personnel in good faith believes is having an anaphylactic reaction; and (iv) administer an opioid antagonist to any person that the school nurse or trained personnel in good faith believes is having an opioid overdose.

(c) The school district, public school, or nonpublic school must inform the parents or guardians of the pupil, in writing, that the school district, public school, or nonpublic school and its employees and agents, including a physician, physician assistant, or advanced practice registered nurse providing standing protocol or prescription for school epinephrine

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

injectors auto-injectors, are to incur no liability or professional discipline, except for willful and wanton conduct, as a result of any injury arising from the administration of asthma medication, an epinephrine injector auto injector, or an opioid antagonist regardless of whether authorization was given by the pupil's parents or quardians or by the pupil's physician, physician assistant, or advanced practice registered nurse. The parents or quardians of the pupil must sign a statement acknowledging that the school district, public school, or nonpublic school and its employees and agents are to incur no liability, except for willful and wanton conduct, as a result of any injury arising from the administration of asthma medication, an epinephrine injector auto-injector, or an opioid antagonist regardless of whether authorization was given by the pupil's parents or guardians or by the pupil's physician, physician assistant, or advanced practice registered nurse and that the parents or guardians must indemnify and hold harmless the school district, public school, or nonpublic school and its employees and agents against any claims, except a claim based on willful and wanton conduct, arising out of the administration of asthma medication, an epinephrine injector auto-injector, opioid antagonist regardless of whether authorization was given by the pupil's parents or guardians or by the pupil's physician, physician assistant, or advanced registered nurse.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

(c-5) When a school nurse or trained personnel administers an undesignated epinephrine injector auto-injector to a person whom the school nurse or trained personnel in good faith believes is having an anaphylactic reaction or administers an opioid antagonist to a person whom the school nurse or trained personnel in good faith believes is having an opioid overdose, notwithstanding the lack of notice to the parents or guardians of the pupil or the absence of the parents or quardians signed statement acknowledging no liability, except for willful and wanton conduct, the school district, public school, nonpublic school and its employees and agents, and a physician, a physician assistant, or an advanced practice registered nurse providing standing protocol or prescription for undesignated epinephrine injectors auto-injectors, are to liability or professional discipline, except for willful and wanton conduct, as a result of any injury arising from the use of an undesignated epinephrine injector auto injector or the use of an opioid antagonist regardless of whether authorization was given by the pupil's parents or guardians or by the pupil's physician, physician assistant, or advanced practice registered nurse.

(d) The permission for self-administration and self-carry of asthma medication or the self-administration and self-carry of an epinephrine <u>injector</u> auto-injector is effective for the school year for which it is granted and shall be renewed each subsequent school year upon fulfillment of the requirements of

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

this Section.

- (e) Provided that the requirements of this Section are fulfilled, a pupil with asthma may self-administer and self-carry his or her asthma medication or a pupil may self-administer and self-carry an epinephrine injector in school, auto injector (i) while (ii) while school-sponsored activity, (iii) while under the supervision of school personnel, or (iv) before or after normal school activities, such as while in before-school or after-school care on school-operated property or while being transported on a school bus.
- (e-5) Provided that the requirements of this Section are fulfilled, a school nurse or trained personnel may administer an undesignated epinephrine <u>injector</u> auto-injector to any person whom the school nurse or trained personnel in good faith believes to be having an anaphylactic reaction (i) while in school, (ii) while at a school-sponsored activity, (iii) while under the supervision of school personnel, or (iv) before or after normal school activities, such as while in before-school or after-school care on school-operated property or while being transported on a school bus. A school nurse or trained personnel may carry undesignated epinephrine <u>injectors</u> auto-injectors on his or her person while in school or at a school-sponsored activity.
- (e-10) Provided that the requirements of this Section are fulfilled, a school nurse or trained personnel may administer

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

an opioid antagonist to any person whom the school nurse or trained personnel in good faith believes to be having an opioid overdose (i) while in school, (ii) while at a school-sponsored activity, (iii) while under the supervision of school personnel, or (iv) before or after normal school activities, such as while in before-school or after-school care on school-operated property. A school nurse or trained personnel may carry an opioid antagonist on their person while in school or at a school-sponsored activity.

(f) The school district, public school, or nonpublic school may maintain a supply of undesignated epinephrine injectors auto-injectors in any secure location that is accessible before, during, and after school where an allergic person is most at risk, including, but not limited to, classrooms and lunchrooms. A physician, a physician assistant who has been delegated prescriptive authority in accordance with Section 7.5 of the Physician Assistant Practice Act of 1987, or an advanced practice registered nurse who has been delegated prescriptive authority in accordance with Section 65-40 of the Nurse Practice Act may prescribe undesignated epinephrine injectors auto-injectors in the name of the school district, public school, or nonpublic school to be maintained for use of necessary. Any supply epinephrine injectors auto-injectors shall be maintained in accordance with the manufacturer's instructions.

The school district, public school, or nonpublic school may

maintain a supply of an opioid antagonist in any secure location where an individual may have an opioid overdose. A health care professional who has been delegated prescriptive authority for opioid antagonists in accordance with Section 5-23 of the Alcoholism and Other Drug Abuse and Dependency Act may prescribe opioid antagonists in the name of the school district, public school, or nonpublic school, to be maintained for use when necessary. Any supply of opioid antagonists shall be maintained in accordance with the manufacturer's instructions.

(f-3) Whichever entity initiates the process of obtaining undesignated epinephrine <u>injectors</u> auto-injectors and providing training to personnel for carrying and administering undesignated epinephrine <u>injectors</u> auto-injectors shall pay for the costs of the undesignated epinephrine <u>injectors</u> auto-injectors

(f-5) Upon any administration of an epinephrine <u>injector</u> auto <u>injector</u>, a school district, public school, or nonpublic school must immediately activate the EMS system and notify the student's parent, guardian, or emergency contact, if known.

Upon any administration of an opioid antagonist, a school district, public school, or nonpublic school must immediately activate the EMS system and notify the student's parent, guardian, or emergency contact, if known.

(f-10) Within 24 hours of the administration of an undesignated epinephrine <u>injector</u> auto injector, a school

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

district, public school, or nonpublic school must notify the physician, physician assistant, or advanced practice registered nurse who provided the standing protocol or prescription for the undesignated epinephrine <u>injector</u> auto injector of its use.

Within 24 hours after the administration of an opioid antagonist, a school district, public school, or nonpublic school must notify the health care professional who provided the prescription for the opioid antagonist of its use.

epinephrine <u>injector</u> auto-injector, trained personnel must submit to their school's administration proof of completion of a training curriculum to recognize and respond to anaphylaxis that meets the requirements of subsection (h) of this Section. Training must be completed annually. The school district, public school, or nonpublic school must maintain records related to the training curriculum and trained personnel.

Prior to the administration of an opioid antagonist, trained personnel must submit to their school's administration proof of completion of a training curriculum to recognize and respond to an opioid overdose, which curriculum must meet the requirements of subsection (h-5) of this Section. Training must be completed annually. Trained personnel must also submit to administration proof school's of cardiopulmonary resuscitation automated external defibrillator and certification. The school district, public school, or

1	nonpublic school must maintain records relating to the training
2	curriculum and the trained personnel.

- (h) A training curriculum to recognize and respond to anaphylaxis, including the administration of an undesignated epinephrine <u>injector</u> auto <u>injector</u>, may be conducted online or in person.
 - Training shall include, but is not limited to:
 - (1) how to recognize signs and symptoms of an allergic reaction, including anaphylaxis;
 - (2) how to administer an epinephrine <u>injector</u> auto-injector; and
 - (3) a test demonstrating competency of the knowledge required to recognize anaphylaxis and administer an epinephrine <u>injector</u> auto-injector.
- Training may also include, but is not limited to:
 - (A) a review of high-risk areas within a school and its related facilities;
 - (B) steps to take to prevent exposure to allergens;
 - (C) emergency follow-up procedures;
 - (D) how to respond to a student with a known allergy, as well as a student with a previously unknown allergy; and
 - (E) other criteria as determined in rules adopted pursuant to this Section.

In consultation with statewide professional organizations representing physicians licensed to practice medicine in all of its branches, registered nurses, and school nurses, the State

Board of Education shall make available resource materials consistent with criteria in this subsection (h) for educating trained personnel to recognize and respond to anaphylaxis. The State Board may take into consideration the curriculum on this subject developed by other states, as well as any other curricular materials suggested by medical experts and other groups that work on life-threatening allergy issues. The State Board is not required to create new resource materials. The State Board shall make these resource materials available on its Internet website.

(h-5) A training curriculum to recognize and respond to an opioid overdose, including the administration of an opioid antagonist, may be conducted online or in person. The training must comply with any training requirements under Section 5-23 of the Alcoholism and Other Drug Abuse and Dependency Act and the corresponding rules. It must include, but is not limited to:

- (1) how to recognize symptoms of an opioid overdose;
- 19 (2) information on drug overdose prevention and 20 recognition;
 - (3) how to perform rescue breathing and resuscitation;
- 22 (4) how to respond to an emergency involving an opioid 23 overdose;
 - (5) opioid antagonist dosage and administration;
 - (6) the importance of calling 911;
- 26 (7) care for the overdose victim after administration

3

4

5

6

7

8

9

10

11

12

15

16

17

18

22

23

24

25

26

	L of	the	overdose	antagonist;
--	------	-----	----------	-------------

- (8) a test demonstrating competency of the knowledge required to recognize an opioid overdose and administer a dose of an opioid antagonist; and
 - (9) other criteria as determined in rules adopted pursuant to this Section.
 - (i) Within 3 days after the administration of an undesignated epinephrine <u>injector</u> auto injector by a school nurse, trained personnel, or a student at a school or school-sponsored activity, the school must report to the State Board of Education in a form and manner prescribed by the State Board the following information:
- 13 (1) age and type of person receiving epinephrine 14 (student, staff, visitor);
 - (2) any previously known diagnosis of a severe allergy;
 - (3) trigger that precipitated allergic episode;
 - (4) location where symptoms developed;
 - (5) number of doses administered;
- 19 (6) type of person administering epinephrine (school nurse, trained personnel, student); and
- 21 (7) any other information required by the State Board.

If a school district, public school, or nonpublic school maintains or has an independent contractor providing transportation to students who maintains a supply of undesignated epinephrine <u>injectors</u> auto-injectors, then the school district, public school, or nonpublic school must report

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

- that information to the State Board of Education upon adoption or change of the policy of the school district, public school, nonpublic school, or independent contractor, in a manner as prescribed by the State Board. The report must include the number of undesignated epinephrine <u>injectors</u> auto <u>injectors</u> in supply.
 - (i-5) Within 3 days after the administration of an opioid antagonist by a school nurse or trained personnel, the school must report to the State Board of Education, in a form and manner prescribed by the State Board, the following information:
 - (1) the age and type of person receiving the opioid antagonist (student, staff, or visitor);
 - (2) the location where symptoms developed;
 - (3) the type of person administering the opioid antagonist (school nurse or trained personnel); and
 - (4) any other information required by the State Board.
 - (j) By October 1, 2015 and every year thereafter, the State Board of Education shall submit a report to the General Assembly identifying the frequency and circumstances of epinephrine administration during the preceding academic year. Beginning with the 2017 report, the report shall also contain information on which school districts, public schools, and nonpublic schools maintain or have independent contractors providing transportation to students who maintain a supply of undesignated epinephrine <u>injectors</u> auto injectors. This report

- shall be published on the State Board's Internet website on the date the report is delivered to the General Assembly.
 - (j-5) Annually, each school district, public school, charter school, or nonpublic school shall request an asthma action plan from the parents or guardians of a pupil with asthma. If provided, the asthma action plan must be kept on file in the office of the school nurse or, in the absence of a school nurse, the school administrator. Copies of the asthma action plan may be distributed to appropriate school staff who interact with the pupil on a regular basis, and, if applicable, may be attached to the pupil's federal Section 504 plan or individualized education program plan.
 - (j-10) To assist schools with emergency response procedures for asthma, the State Board of Education, in consultation with statewide professional organizations with expertise in asthma management and a statewide organization representing school administrators, shall develop a model asthma episode emergency response protocol before September 1, 2016. Each school district, charter school, and nonpublic school shall adopt an asthma episode emergency response protocol before January 1, 2017 that includes all of the components of the State Board's model protocol.
 - (j-15) Every 2 years, school personnel who work with pupils shall complete an in-person or online training program on the management of asthma, the prevention of asthma symptoms, and emergency response in the school setting. In consultation with

- 1 statewide professional organizations with expertise in asthma
- 2 management, the State Board of Education shall make available
- 3 resource materials for educating school personnel about asthma
- 4 and emergency response in the school setting.
- 5 (j-20) On or before October 1, 2016 and every year
- 6 thereafter, the State Board of Education shall submit a report
- 7 to the General Assembly and the Department of Public Health
- 8 identifying the frequency and circumstances of opioid
- 9 antagonist administration during the preceding academic year.
- 10 This report shall be published on the State Board's Internet
- 11 website on the date the report is delivered to the General
- 12 Assembly.
- 13 (k) The State Board of Education may adopt rules necessary
- 14 to implement this Section.
- 15 (1) Nothing in this Section shall limit the amount of
- epinephrine injectors auto injectors that any type of school or
- 17 student may carry or maintain a supply of.
- 18 (Source: P.A. 99-173, eff. 7-29-15; 99-480, eff. 9-9-15;
- 19 99-642, eff. 7-28-16; 99-711, eff. 1-1-17; 99-843, eff.
- 20 8-19-16; 100-201, eff. 8-18-17; 100-513, eff. 1-1-18.)